Consensus conference on the use of 90-yt
✍
Umberto Vitolo; Giovanni Barosi; Stefano Fanti; Alessandro M. Gianni; Maurizio M
📂
Article
📅
2010
🏛
John Wiley and Sons
🌐
English
⚖ 161 KB
👁 2 views
90-yttrium-ibritumomab-tiuxetan is approved for treatment of rituximab-relapsed/refractory CD201 follicular B-cell lymphoma and as consolidation therapy in untreated follicular lymphoma. Recommendations on the use of 90-yttrium-ibritumomab tiuxetan were issued in a consensus conference, sponsored by